This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
Hydergine (Ergoloid Mesylates)
One of the oldest and most studied nootropic drugs - a mixture of ergot alkaloids developed in the 1940s that enhances cerebral blood flow, neuronal metabolism, and has been prescribed for cognitive decline for decades.
Benefits
What is Hydergine (Ergoloid Mesylates)?
Hydergine (ergoloid mesylates) is a mixture of dihydrogenated ergot alkaloids developed by Albert Hofmann - the same chemist who discovered LSD - at Sandoz Laboratories in 1949. It consists of equal proportions of dihydroergocornine, dihydroergocristine, and dihydro-alpha and beta-ergocryptine mesylates. Hydergine holds the distinction of being one of the first drugs specifically developed and approved for age-related cognitive decline, receiving FDA approval in 1978.
For decades, Hydergine was one of the most prescribed drugs in the world for cognitive enhancement, with peak sales exceeding $2 billion annually. A 1994 Cochrane-style meta-analysis by Thompson et al. covering 47 randomised controlled trials with over 3,000 patients found statistically significant improvements in cognitive function, mood, and global clinical impression in elderly patients with dementia or cognitive decline. Its mechanisms are multifaceted: it improves cerebral blood flow and oxygen utilisation, acts as a free radical scavenger, stabilises neuronal membranes, increases dopaminergic and serotonergic activity, and enhances nerve growth factor sensitivity. While it has been largely superseded by newer drugs (cholinesterase inhibitors, memantine) for Alzheimer's treatment, it retains a dedicated following in the nootropics community for its unique multi-target neuroprotective profile and decades of demonstrated clinical safety.
- Cerebral blood flow enhancement: Improves oxygen delivery and glucose utilisation in the brain by dilating cerebral blood vessels and improving microcirculation
- Free radical scavenging: Directly neutralises superoxide and hydroxyl radicals, protecting neuronal membranes from oxidative damage
- Dopaminergic activity: Partial agonist at dopamine D2 receptors, enhancing dopaminergic transmission in the prefrontal cortex
- Serotonergic activity: Partial agonist at serotonin 5-HT2A receptors, contributing to mood enhancement and neuroplasticity
- Adrenergic blockade: Alpha-adrenergic antagonist properties reduce sympathetic vasoconstriction, further improving cerebral blood flow
- NGF sensitivity: Enhances neuronal sensitivity to nerve growth factor, supporting neuronal survival and synaptic maintenance in ageing
- Standard dosage: 3-6 mg per day, divided into 3 doses taken with meals
- Nootropic community dosage: Some users take up to 9-12 mg per day, though this exceeds standard clinical recommendations
- Clinical dosage: FDA-approved dosage was 3 mg per day in divided doses for age-related cognitive decline
- Sublingual: Some users dissolve tablets sublingually for faster absorption, though this is not the standard route
- Onset: Acute effects on alertness within 1-2 hours. Full cognitive benefits develop over 4-12 weeks of consistent use
- Decades of clinical safety: Prescribed to millions of patients worldwide since the 1950s with an excellent safety record
- Mild side effects: Occasional nausea, headache, dizziness, and mild GI discomfort. Generally very well tolerated
- Hypotension: May lower blood pressure due to alpha-adrenergic blocking effects. Use caution in individuals with low blood pressure or those taking antihypertensives
- Ergot sensitivity: Contraindicated in individuals with known ergot alkaloid sensitivity or allergy
- Availability: Prescription medication in many countries. Availability has decreased as newer dementia drugs have taken its place. Generic versions exist
Natural Sources & Forms
- Prescription tablets: Available as generic ergoloid mesylates in 1 mg tablets (take 3 per day for standard dosage)
- Brand names: Hydergine (Novartis), though brand-name availability varies by country
- International pharmacies: Available from international online pharmacies in countries where it remains marketed
Frequently Asked Questions
One of the oldest and most studied nootropic drugs - a mixture of ergot alkaloids developed in the 1940s that enhances cerebral blood flow, neuronal metabolism, and has been prescribed for cognitive decline for decades.
The key benefits of Hydergine (Ergoloid Mesylates) include: Cognitive Enhancement, Energy, Focus, Longevity, Memory, Mood.
Cerebral blood flow enhancement: Improves oxygen delivery and glucose utilisation in the brain by dilating cerebral blood vessels and improving microcirculation Free radical scavenging: Directly neutralises superoxide and hydroxyl radicals, protecting neuronal membranes from oxidative damage Dopaminergic activity: Partial agonist at dopamine D2 receptors, enhancing dopaminergic transmission in the prefrontal cortex Serotonergic activity: Partial agonist at serotonin 5-HT2A receptors, contributing to mood enhancement and neuroplasticity Adrenergic blockade: Alpha-adrenergic antagonist properties reduce sympathetic vasoconstriction, further improving cerebral blood flow NGF sensitivity: Enhances neuronal sensitivity to nerve growth factor, supporting neuronal survival and synaptic maintenance in ageing
Standard dosage: 3-6 mg per day, divided into 3 doses taken with meals Nootropic community dosage: Some users take up to 9-12 mg per day, though this exceeds standard clinical recommendations Clinical dosage: FDA-approved dosage was 3 mg per day in divided doses for age-related cognitive decline Sublingual: Some users dissolve tablets sublingually for faster absorption, though this is not the standard route Onset: Acute effects on alertness within 1-2 hours. Full cognitive benefits develop over 4-12 weeks of consistent use
Decades of clinical safety: Prescribed to millions of patients worldwide since the 1950s with an excellent safety record Mild side effects: Occasional nausea, headache, dizziness, and mild GI discomfort. Generally very well tolerated Hypotension: May lower blood pressure due to alpha-adrenergic blocking effects. Use caution in individuals with low blood pressure or those taking antihypertensives Ergot sensitivity: Contraindicated in individuals with known ergot alkaloid sensitivity or allergy Availability: Prescription medication in many countries. Availability has decreased as newer dementia drugs have taken its place. Generic versions exist
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!